​

Fulcrum Therapeutics (FULC) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

FULC Stock Forecast

Fulcrum Therapeutics (FULC) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $13.67, with a high of $20.00 and a low of $9.00. This represents a 36.70% increase from the last price of $10.00.

- $4 $8 $12 $16 $20 High: $20 Avg: $13.67 Low: $9 Last Closed Price: $10

FULC Stock Rating

Fulcrum Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (66.67%), 4 Hold (26.67%), 1 Sell (6.67%), and 0 Strong Sell (0.00%).

Buy
Total 15 1 4 10 0 Strong Sell Sell Hold Buy Strong Buy

FULC Price Target Upside V Benchmarks

TypeNameUpside
StockFulcrum Therapeutics36.70%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts124
Avg Price Target$20.00$16.00$13.25
Last Closing Price$10.00$10.00$10.00
Upside/Downside100.00%60.00%32.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25231-17
Sep, 25231-17
Aug, 25231-17
Jul, 25132-17
Jun, 25132-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2025Leerink Partners$20.00$9.22116.92%100.00%
Jul 29, 2025H.C. Wainwright$12.00$7.5958.10%20.00%
May 29, 2025Edward TenthoffPiper Sandler$9.00$7.0926.94%-10.00%
May 23, 2025Joseph SchwartzLeerink Partners$12.00$6.4486.34%20.00%
Sep 13, 2024Andrew FeinH.C. Wainwright$4.00$3.4416.28%-60.00%
Sep 12, 2024Gregory RenzaRBC Capital$4.00$3.4416.28%-60.00%
Sep 12, 2024Dae Gon Ha downgraded Fulcrum TherapeuticsStifel Nicolaus$3.00$3.55-15.49%-70.00%
Sep 12, 2024Tazeen AhmadBank of America Securities$2.00$3.44-41.86%-80.00%
Sep 09, 2024Tazeen AhmadBank of America Securities$10.00$8.6116.14%-
Sep 03, 2024Gregory RenzaRBC Capital$15.00$8.3779.21%50.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2025Leerink PartnersOutperformOutperformhold
Oct 20, 2025H.C. WainwrightBuyBuyhold
May 29, 2025Piper SandlerOverweightOverweighthold
May 14, 2025Cantor FitzgeraldNeutralOverweightupgrade
Sep 13, 2024Leerink PartnersMarket PerformMarket Performhold
Sep 13, 2024H.C. WainwrightHoldNeutraldowngrade
Sep 12, 2024RBC CapitalOutperformSector Performdowngrade
Sep 12, 2024Bank of America SecuritiesNeutralUnderperformdowngrade
Sep 12, 2024Cantor FitzgeraldOverweightNeutraldowngrade
Sep 09, 2024Bank of America SecuritiesUnderperformNeutralupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-2.70$-2.22$-2.35$-1.59-
Avg Forecast$-2.80$-2.47$-2.41$-1.64$-0.15
High Forecast$-2.80$-2.47$-2.41$-1.57$-0.07
Low Forecast$-2.80$-2.47$-2.41$-1.79$-0.21
Surprise %-3.57%-10.12%-2.49%-3.05%-

Revenue Forecast

$0 $17M $34M $51M $68M $85M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$8.82M$19.16M$6.34M$2.81M-
Avg Forecast$5.69M$14.39M$7.35M$2.31M$80.47M
High Forecast$5.69M$14.39M$7.35M$2.90M$80.47M
Low Forecast$5.69M$14.39M$7.35M$2.02M$80.47M
Surprise %55.12%33.21%-13.67%21.21%-

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-68.44M$-78.33M$-105.62M$-97.33M-
Avg Forecast$-171.46M$-151.14M$-148.00M$-97.33M$-9.72M
High Forecast$-171.46M$-151.14M$-148.00M$-96.28M$-4.55M
Low Forecast$-171.46M$-151.14M$-148.00M$-109.69M$-13.07M
Surprise %-60.08%-48.17%-28.64%--

FULC Forecast FAQ

Is Fulcrum Therapeutics stock a buy?

Fulcrum Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Fulcrum Therapeutics is a favorable investment for most analysts.

What is Fulcrum Therapeutics's price target?

Fulcrum Therapeutics's price target, set by 15 Wall Street analysts, averages $13.67 over the next 12 months. The price target range spans from $9 at the low end to $20 at the high end, suggesting a potential 36.70% change from the previous closing price of $10.

How does Fulcrum Therapeutics stock forecast compare to its benchmarks?

Fulcrum Therapeutics's stock forecast shows a 36.70% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Fulcrum Therapeutics over the past three months?

  • October 2025: 28.57% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 14.29% Strong Sell.
  • September 2025: 28.57% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 14.29% Strong Sell.
  • August 2025: 28.57% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 14.29% Strong Sell.

What is Fulcrum Therapeutics’s EPS forecast?

Fulcrum Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.15, marking a -90.57% decrease from the reported $-1.59 in 2023..

What is Fulcrum Therapeutics’s revenue forecast?

Fulcrum Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $80.47M, reflecting a 2768.88% increase from the reported $2.8M in 2023.

What is Fulcrum Therapeutics’s net income forecast?

Fulcrum Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-9.725M, representing a -90.01% decrease from the reported $-97.335M in 2023.